RECURRENT FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug Q702 aims to boost immune system against blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has returned or not responded to prior therapies. About 22 adults with grade 1-3a lymphoma will receive the combination. The goal is to improve cancer remissio…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:23 UTC